London SME providing electronic instrumentation and systems for magnetic hyperthermia and nanotechnology-enabled medical device development.
Resonant Circuits Limited is a London-based technology SME specialising in the hardware and electronic systems that underpin magnetic hyperthermia — a cancer treatment approach that uses alternating magnetic fields to heat targeted nanoparticles inside tumours. Their name points directly to their technical niche: the resonant electromagnetic circuits used to generate precise alternating magnetic fields in clinical and pre-clinical settings. In H2020, they contributed to the engineering and upscaling of nanomedicine-based cancer therapy systems and, more recently, to safety testing frameworks for nanotechnology-enabled medical devices. Their value to a consortium is specialist hardware or instrumentation expertise at the intersection of electronics and biomedical application.
NoCanTher (2016-2021) focused on multimodal cancer therapy using multifunctionalised magnetic nanoparticles, where resonant circuit hardware is the core enabling technology for controlled field generation.
NoCanTher targeted Phase I clinical trials and GMP upscaling of nanoparticle-based therapies for pancreatic cancer, implying hands-on involvement in translating lab systems to regulated clinical-grade environments.
SAFE-N-MEDTECH (2019-2023) addressed safety testing across the lifecycle of nanotechnology-enabled medical devices and in vitro diagnostics, broadening their role from therapy delivery to regulatory-grade validation.
SAFE-N-MEDTECH introduced medical devices and in vitro diagnostics as explicit keyword domains, signalling a step toward the broader medtech product landscape beyond cancer therapy.
In their earliest H2020 engagement (2016), Resonant Circuits was embedded in a highly focused cancer therapy application — magnetic hyperthermia for pancreatic cancer, GMP upscaling, and Phase I clinical translation. By 2019, the language of their work shifted from disease-specific therapy toward the broader regulatory and safety infrastructure for nanotechnology-enabled medical devices generally, including in vitro diagnostics. This suggests a deliberate move from being a component supplier within a specific clinical programme toward positioning themselves as a cross-cutting technical partner in the medical device safety and validation ecosystem.
They appear to be broadening from a single-disease application (pancreatic cancer hyperthermia) toward platform-level safety and regulatory capabilities applicable across the nano-enabled medical device sector — making them increasingly relevant to any consortium needing medtech compliance expertise.
Resonant Circuits participates exclusively as a partner — they have never coordinated an H2020 project — which places them in a specialist contributor role rather than a consortium leadership one. Despite only two projects, they have accumulated 43 unique partners across 16 countries, reflecting integration into large, multi-partner European research consortia typical of RIA and IA instruments. This suggests they are sought out for a specific technical function rather than for network orchestration, and they are comfortable operating inside complex multi-stakeholder project structures.
With 43 unique consortium partners spread across 16 countries from just two projects, their network density per project is high, indicating participation in large pan-European consortia rather than bilateral arrangements. No repeated partner patterns are detectable with only two data points, so geographic loyalties remain unclear.
Resonant Circuits occupies a narrow but strategically valuable niche: the electronic and instrumentation layer of nanomedicine, specifically the hardware that makes magnetic hyperthermia clinically viable. Very few SMEs combine electronics expertise with GMP-level nanomedicine translation and medical device safety testing — most actors in this space are either university labs or large medtech firms. For a consortium building a clinical nanomedicine programme or a nano-medtech safety project, they offer engineering credibility that academic partners cannot provide and the agility that large companies lack.
